XML 25 R15.htm IDEA: XBRL DOCUMENT

Research and Development (R&D) Funding Expense	3 Months Ended
Research and Development (R&D) Funding Expense	Mar. 31, 2024
Research and Development [Abstract]
Research and Development (R&D) Funding Expense	Research and Development (R&D) Funding Expense R&D funding expense consists of payments that we have made to counterparties to acquire royalties or milestones on product candidates. R&D funding expense includes development-stage funding payments made to counterparties on an upfront basis or upon pre-approval milestones, and development-stage funding payments that are made to counterparties over time as the related product candidates undergo clinical trials with our counterparties. During the first quarter of 2024 and 2023, we did not enter into any new ongoing R&D funding arrangements. We recognized R&D funding expense of $0.5 million in each of the first quarter of 2024 and 2023 related to ongoing development-stage funding payments.